Feb 20 (Reuters) - Eli Lilly (LLY.N), opens new tab is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million ...

Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the pharmaceutical company from preparing for its launch.

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

New pricing aims to attract cash-paying customers via LillyDirect Hims & Hers warns it may stop selling compounded version of Novo Nordisk weight-loss drugs Telehealth firms' shares fall The move ...

Danish drugmaker Novo Nordisk and Eli Lilly currently dominate the market for weight-loss treatments with their injectable drugs. Novo is studying the pill version of its experimental drug ...

As chief scientific officer at Eli Lilly, he's already done it once with the company's weekly shot, Zepbound. He's trying to do it again with a more convenient daily pill, then repeat the feat ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial ...